{"disease":{"id":"squamous-cell-carcinoma-of-skin","name":"squamous cell carcinoma of skin"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03621462","title":"Elucid Labs AIDA™ - Labelled Image Acquisition Protocol","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Elucid Labs Inc.","has_results":false},{"nct_id":"NCT06661577","title":"An Observational Study Using The LumAssure Device In Participants Undergoing Assessment Of Skin Conditions.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"University of Auckland, New Zealand","has_results":false},{"nct_id":"NCT07347392","title":"The Role of Radiotherapy for the Management of Non-melanoma Skin Cancer in Denmark.","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2900,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT07361666","title":"Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","has_results":false},{"nct_id":"NCT05302297","title":"Comparative Efficacy of Cemiplimab to Historical Standard of Care in France","phase":"","overall_status":"COMPLETED","enrollment_count":305,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT06606028","title":"Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04892849","title":"Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT03589339","title":"NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":145,"lead_sponsor_name":"Nanobiotix","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05482880","title":"Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region","phase":"","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT04348916","title":"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":66,"lead_sponsor_name":"Oncorus, Inc.","has_results":false},{"nct_id":"NCT03325738","title":"Cetuximab for Unresectable Cutaneous Squamous Cell Carcinoma - A National Retrospective Study","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Centre Antoine Lacassagne","has_results":false},{"nct_id":"NCT06444815","title":"A Study of VET3-TGI in Patients With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"KaliVir Immunotherapeutics","has_results":false},{"nct_id":"NCT03370861","title":"How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes","phase":"","overall_status":"TERMINATED","enrollment_count":54,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03894618","title":"SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Shattuck Labs, Inc.","has_results":true},{"nct_id":"NCT04913220","title":"A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":46,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT05246228","title":"Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy","phase":"","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","has_results":false},{"nct_id":"NCT05144698","title":"RAPA-201 Therapy of Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Rapa Therapeutics LLC","has_results":false},{"nct_id":"NCT05574101","title":"A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04812535","title":"Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":30,"lead_sponsor_name":"InflaRx GmbH","has_results":true},{"nct_id":"NCT06753136","title":"Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype","phase":"NA","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT05886140","title":"Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin","phase":"NA","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT07311057","title":"Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":20,"lead_sponsor_name":"Daryoush Hamidi Alamdari, PhD","has_results":false},{"nct_id":"NCT05490485","title":"Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT02324608","title":"Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT06046625","title":"Needs and Preferences of Patients With Head-neck Cutaneous SCC","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT04480645","title":"CivaDerm(TM) Surface Therapy Pilot Study","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"CivaTech Oncology","has_results":false},{"nct_id":"NCT02218164","title":"Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT03737721","title":"The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"AHS Cancer Control Alberta","has_results":false}],"total":31},"guidelines":[],"source":"Drug Landscape verified database"}